Q2 2023
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
New | ARCELLX INC | $124,792,441 | – | 3,946,630 | – | 53.81% | – | |
DSGN | New | DESIGN THERAPEUTICS INC | $41,116,799 | – | 6,526,476 | – | 17.73% | – |
New | MINERALYS THERAPEUTICS INC | $30,597,930 | – | 1,794,600 | – | 13.19% | – | |
SBTX | New | ARS PHARMACEUTICALS INC | $26,886,450 | – | 4,012,903 | – | 11.59% | – |
New | EFFECTOR THERAPEUTICS INC | $5,594,133 | – | 6,822,114 | – | 2.41% | – | |
NKTX | New | NKARTA INC | $2,919,999 | – | 1,333,333 | – | 1.26% | – |
Q4 2022
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
Exit | EFFECTOR THERAPEUTICS INC | $0 | – | -6,822,114 | – | -1.78% | – | |
NKTX | Exit | NKARTA INC. | $0 | – | -1,333,333 | – | -8.02% | – |
DSGN | Exit | DESIGN THERAPEUTICS INC | $0 | – | -5,626,476 | – | -43.01% | – |
Exit | ARCELLX INC. | $0 | – | -5,500,007 | – | -47.19% | – |
Q2 2022
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
New | ARCELLX INC. | $99,440,000 | – | 5,500,007 | – | 48.67% | – | |
DSGN | New | DESIGN THERAPEUTICS INC | $78,771,000 | – | 5,626,476 | – | 38.55% | – |
NKTX | New | NKARTA INC. | $16,427,000 | – | 1,333,333 | – | 8.04% | – |
New | EFFECTOR THERAPEUTICS INC | $9,687,000 | – | 6,822,114 | – | 4.74% | – |